Treatment for Sedentary Behaviors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Gramercy Research Group, Winston-Salem, NC
Sedentary Behaviors+3 More
Eligibility
18+
Female
What conditions do you have?
Select

Study Summary

This study will identify strategies for modifying a physical activity intervention, previously delivered in a face-to-face format, for online implementation.

Eligible Conditions

  • Sedentary Behaviors
  • Lack of Physical Activity
  • Physical Inactivity

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: Month 20

Month 20
Feasibility and acceptability of the online curricula from advisory team members
Month 9
Factors needed to adapt a group-based in-person intervention for online implementation

Trial Safety

Safety Progress

1 of 3

Trial Design

0 Treatment Group

60 Total Participants · 0 Treatment Group

Primary Treatment: Treatment · No Placebo Group · N/A

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: month 20

Trial Background

Melicia Whitt-Glover, President & CEO
Principal Investigator
Gramercy Research Group
Closest Location: Gramercy Research Group · Winston-Salem, NC
2014First Recorded Clinical Trial
1 TrialsResearching Sedentary Behaviors
2 CompletedClinical Trials

Eligibility Criteria

Age 18+ · Female Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are self-reported as having low active.
You have no physical limitations or medical conditions that would be impacted by physical activity.
You are able to read and write English fluently; 8) potentially interested in participating in an online health intervention.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.